Diagnosis of B-ALL by flow cytometry, bone marrow histology, and/or cytogenetics
Relapsed/refractory disease after at least 2 cycles of standard multiagent induction chemotherapy. For subjects with Philadelphia-chromosome positive (Ph+) disease, failure or intolerance to a tyrosine kinase inhibitor therapy-containing regimen
ALL SUBJECTS:
Capable of giving signed informed consent
Age ≥ 18 years old
Stated willingness to comply with study procedures and duration
Contraceptive use for women and men as defined in the protocol
You may not be if
ALL SUBJECTS:
Females who are pregnant or breastfeeding
Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2
Body weight \<50 kg
Evidence of insufficient organ function
Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to Day 1
Currently receiving or likely to require systemic immunosuppressive therapy
Ongoing requirement for systemic GvHD therapy following prior allogeneic hematopoietic stem cell transplant (HSCT) or allogeneic CAR-T
Receipt of an allograft organ transplant
Known active central nervous system (CNS) involvement by malignancy
Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
Clinically significant cardiovascular disease
Positive serologic test results for HIV infection
Positive serologic and polymerase chain reaction (PCR) test results for Hepatitis B (HBV) infection
Positive serologic and PCR test results for Hepatitis C (HCV) infection
Live vaccine \<6 weeks prior to start of lympho-conditioning
